Azelis expands its pharma and nutraceutical offering to United Kingdom & Ireland

26 July 2021

Azelis, a leading innovation service provider in the specialty chemicals and food ingredients industry, is pleased to announce a new distribution agreement with SPI Pharma, a leading supplier of solutions to pharmaceutical formulation marketers. Azelis will distribute SPI Pharma’s product line in the United Kingdom and Ireland.


Highlights & rationale                                                                               

  • This new partnership extends the organoleptic excipients in Azelis’ range, complementing the existing starch derivatives & sugars, flavors and sucralose
  • This alliance also expands Azelis’ antacid actives for pharmaceuticals and highly bioavailable metal salts for the nutraceuticals market
  • This new distribution agreement furthers Azelis’ strategy of organic growth with leading partners 


SPI Pharma’s primary objective is to engineer functional materials allowing for formulation solving and differentiation. SPI Pharma's product line fits well into the strategy of Azelis, to offer technical excipients with synergies that complement one another. This agreement covers product lines including mannitol, fructose, maltose, antacid actives, metal salts, surface modified sodium bicarbonate, ODT drug delivery systems and veterinary vaccine adjuvants. The additional products from SPI Pharma in combination with existing flavors and sweeteners in Azelis’ portfolio allow for new formulations, chewable tablets, nutraceutical tablets, and more.


Trevor Bridger, Business Manager Pharma, UK, Ireland & Developing Markets at Azelis, comments: 

“We are delighted to enter into this new agreement. SPI Pharma offers a strong range of technical raw materials and are proven innovators in the field, particularly with their range of mannitol excipients. Their range of organoleptic excipients will certainly be of interest to formulators of chewable pharmaceuticals and nutraceuticals, and will offer unique formulation properties. We look forward to working on blue sky concepts in our application labs and bringing this great line of products to customers across the United Kingdom and Ireland.”


John McInerney, General Manager Excipients and Drug Delivery Systems Business Unit at SPI Pharma, adds: 

With this new agreement, we’re confident that Azelis is the right partner for the distribution of our products. Azelis and SPI Pharma have a like-minded approach to specialty excipients and technical selling, and a very complementary product range. Azelis’ application labs and the ability to formulate with our excipients and actives is something we are excited to see in action. With their skilled team, we look forward to seeing the great results they will bring in the United Kingdom & Ireland.”


With over 60 application labs around the world, each dedicated to a single market segment, Azelis is constantly working on innovative projects with customers and suppliers. Azelis has two EMEA pharma application labs, in the United Kingdom and Turkey, staffed by industry experts working to support customers and principals with new product development, formulations, and more.